Bio-Works Technologies AB has confirmed that they have received two new orders from contract manufacturer Catalent Biologics for a total order value of 778 KSEK (94,512 USD). The orders are expected to ship in the second half of this year.

“We are proud that Catalent Biologics has chosen Bio-Works to supply chromatography resins for this project. Catalent Biologics is a fast-growing, global contract manufacturer with innovative technologies and integrated solutions that are leveraged by companies ranging from small biotech to large biopharma. Their deep expertise and patient first mindset aligns closely with our dedication to high quality products and industry leading customer service,” said Jonathan Royce, CEO of Bio-Works Technologies.

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With state-of-the-art facilities in North America and Europe, Catalent Biologics provides end-to-end solutions to simplify and de-risk the path from pre-clinical stage through commercial launch and beyond. They have 20+ years’ expertise in biologics development and manufacturing, with 45+ commercially-approved products manufactured in their sites to date.

Bio-Works designs, develops, manufactures and supplies innovative leading-edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. Bio-Works’ agarose based high performance products are used for purification in the life science research phases as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally with our own organization and via distributors. The Bio-Works’ headquarter with R&D and manufacturing is located in Uppsala Business Park in Uppsala, Sweden and the company processes and a Quality Management System follow the standards of ISO 9001:2015.